BIOLOGIC AGENTS FOR PSORIASIS
Since the late 1990s, the use of biologics for psoriasis has been showcased in the dermatology literature and in educational meetings. Most of the literature has focused on the safety and efficacy data generated from clinical trials. The aim of this issue is to take this discussion one step further and examine the incorporation of these agents successfully into clinical practice.
The aim of this issue is to take this discussion one step further and examine the incorporation of these agents successfully into clinical practice.
This article reviews how an increased understanding of the pathophysiology of psoriasis led to the development of these products.
Alefacept for the Treatment of Psoriasis: A Review of the Current Literature and Practical Suggestions for Everyday Clinical Use
PDF NOT AVAILABLE. Contact firstname.lastname@example.org for a copy of the article.
In this article, clinical trial data and case reports illustrate recommended patient management techniques and the substantial long-term benefits that psoriasis patients may realize with efalizumab therapy.
This chapter reviews etanercept (Enbrel®, Amgen and Wyeth, Thousand Oaks, CA), the first TNF- inhibitor approved by the Food and Drug Administration (FDA) for the treatment of not only plaque psoriasis but also psoriatic arthritis (PsA). Both efficacy and safety data for etanercept will be discussed, and a practical approach for the use of this drug in the dermatologic practice will be outlined.